Shestruma Parajuli
Research Subjects
Research Interests
Shestruma Parajuli has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Aferdita Spahillari
Department of Medicine. Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA
1 shared publication - Allison M. Keeler
Department of Genetic & Cellular Medicine, Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, USA
1 shared publication Ana Rita Batista
Department of Neurology, University of Massachusetts Chan Medical School
1 shared publication- Angela Lek
Department of Genetics, Yale School of Medicine, New Haven, CT, USA
1 shared publication - Brenda Wong
University of Massachusetts Chan Medical School
1 shared publication Choukri Mekkaoui
1 shared publication
Latest Publications
- Open Access
Unexpected Death of a Duchenne Muscular Dystrophy Patient in an N-of-1 Trial of rAAV9-delivered CRISPR-transactivator
An N-of-1 trial was developed to deliver a dCas9-VP64 transgene designed to upregulate the cortical dystrophin as a custom therapy for a Duchenne muscular dystrophy (DMD) patient. After showing signs of mild cardiac dysfunction and pericardial effusion, the patient acutely decompensated and sustained cardiac arrest six-days after dosing and succumbed two-days later. Post-mortem examination revealed severe acute-respiratory distress syndrome with diffuse alveolar damage. Vector biodistribution data was obtained and revealed minimal expression of transgene in liver. There was no evidence of AAV9 antibodies nor of effector T cell reactivity. These findings demonstrate innate immune signaling with capillary leak as a form of toxicity in an advanced DMD case treated with high-dose rAAV gene therapy.
Open AccessUnexpected Death of a Duchenne Muscular Dystrophy Patient in an N-of-1 Trial of rAAV9-delivered CRISPR-transactivator
An N-of-1 trial was developed to deliver a dCas9-VP64 transgene designed to upregulate the cortical dystrophin as a custom therapy for a Duchenne muscular dystrophy (DMD) patient. After showing signs of mild cardiac dysfunction and pericardial effusion, the patient acutely decompensated and sustained cardiac arrest six-days after dosing and succumbed two-days later. Post-mortem examination revealed severe acute-respiratory distress syndrome with diffuse alveolar damage. Vector biodistribution data was obtained and revealed minimal expression of transgene in liver. There was no evidence of AAV9 antibodies nor of effector T cell reactivity. These findings demonstrate innate immune signaling with capillary leak as a form of toxicity in an advanced DMD case treated with high-dose rAAV gene therapy.
- 1 June 2021
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 3 (3) , e200580
Accelerated in Vivo Cardiac Diffusion-Tensor MRI Using Residual Deep Learning–based Denoising in Participants with Obesity
A deep learning denoising algorithm was developed to accelerate diffusion-tensor MRI (DT-MRI) data acquisition to preserve image quality and cardiac DT-MRI parameter quantification. Purpose To develop and assess a residual deep learning algorithm to accelerate in vivo cardiac diffusion-tensor MRI (DT-MRI) by reducing the number of averages while preserving image quality and DT...
- 1 June 2021
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 3 (3) , e200580
Accelerated in Vivo Cardiac Diffusion-Tensor MRI Using Residual Deep Learning–based Denoising in Participants with Obesity
A deep learning denoising algorithm was developed to accelerate diffusion-tensor MRI (DT-MRI) data acquisition to preserve image quality and cardiac DT-MRI parameter quantification. Purpose To develop and assess a residual deep learning algorithm to accelerate in vivo cardiac diffusion-tensor MRI (DT-MRI) by reducing the number of averages while preserving image quality and DT...